ALXO ALX Oncology Holdings Inc.

82.42
-1.45  -2%
Previous Close 83.87
Open 84.06
52 Week Low 28.01
52 Week High 117.45
Market Cap $3,058,401,963
Shares 37,107,522
Float 20,768,939
Enterprise Value $2,858,483,870
Volume 77,959
Av. Daily Volume 204,529
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ALX148 and Keytruda
Head and neck squamous cell carcinoma (HNSCC)
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ALX148 and azacitidine (ASPEN-02)
Myelodysplastic syndromes (MDS)
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
ALX148 and trastuzumab (Herceptin) - (ASPEN-01)
Solid Tumors and Lymphoma
Phase 1
Phase 1
Phase 1 data presented at ASH December 2020 noted objective response rates (ORR) of 41% and 70% across two dosing regimens.
ALX148 + Herceptin (trastuzumab) + Cyramza ramucirumab and paclitaxel (ASPEN-06)
2nd line or greater gastric/gastroesophageal junction cancer
Phase 2
Phase 2
Phase 2 trial to be initiated 2H 2021.
ALX148 in combination with azacitidine and venetoclax
Acute myeloid leukemia (AML)
Phase 1
Phase 1
Phase 1 trial to be initiated 2H 2021.

Latest News

  1. BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021.

    "2020 was a year of numerous corporate and clinical accomplishments. Following our successful IPO in July and upsized secondary offering last month, we secured gross proceeds of approximately $394 million which provides the cash to fund our clinical development plans through 2024. During the year, we initiated several clinical trials evaluating our lead candidate, ALX148, in both hematologic and solid tumors and were highly encouraged by the…

    BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021.

    "2020 was a year of numerous corporate and clinical accomplishments. Following our successful IPO in July and upsized secondary offering last month, we secured gross proceeds of approximately $394 million which provides the cash to fund our clinical development plans through 2024. During the year, we initiated several clinical trials evaluating our lead candidate, ALX148, in both hematologic and solid tumors and were highly encouraged by the multiple data readouts in patients with HER2 positive gastric/gastroesophageal junction cancer and head and neck cancer that were recently reported at 35th Annual SITC meeting," said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology.

    "2021 is expected to be another exciting and productive year with additional clinical trial initiations and data readouts that we expect to further validate and distinguish ALX148 from other CD47 targeted approaches. We also look forward to initiating our collaboration with Zymeworks to evaluate ALX148 in combination with zanidatamab and providing additional updates on our development programs during the year," Dr. Pons stated.

    Anticipated Key Milestones for 2021

    • Phase 1b full data read out for ALX148 in combination with Merck's Keytruda® (pembrolizumab) and chemotherapy for the treatment of patients with head and neck squamous cell carcinoma (HNSCC) is planned in the first half of 2021.

    • Initiation of two randomized Phase 2 studies for ALX 148 in combination with Keytruda in patients with HNSCC are planned in the first half of 2021. The first study (ASPEN-03) will evaluate the efficacy of ALX148 in combination with KEYTRUDA for the first line treatment of patients with PD-L1 expressing metastatic or unresectable, recurrent HNSCC. The second study (ASPEN-04) will evaluate ALX148 in combination with KEYTRUDA and standard chemotherapy for the first line treatment of patients with metastatic or unresectable, recurrent HNSCC.

    • Initiation of a Phase 1b clinical trial in the first half of 2021 with ALX148 in combination with Zymeworks' zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors.

    • Initiation of a Phase 1 clinical trial evaluating ALX148 in combination with azacitidine and venetoclax in acute myeloid leukemia (AML) (ASPEN-05) patients in the second half of 2021.

    • Initiation of a randomized Phase 2 trial of ALX148 in combination with Herceptin® (trastuzumab), Cyramza® (ramucirumab) and paclitaxel in patients with 2nd line or greater gastric/gastroesophageal junction cancer (ASPEN-06) is expected in the second half of 2021.

    • Results of a Phase 1 clinical trial of ALX 148 in combination with azacitidine in patients with myelodysplastic syndromes (MDS) and the initiation of the Phase 2 clinical trial in MDS (ASPEN-02) are expected in the fourth quarter 2021.

    • Announcements of potential initiation of additional clinical trials and investigator sponsored trials in additional solid tumor indications are expected during 2021.

    Cash Position and Financial Guidance

    ALX Oncology ended the third quarter of 2020 with approximately $259.5 million in cash, cash equivalents. In December, ALX Oncology completed an upsized public offering of common stock which raised gross proceeds of $208 million including the exercise of the underwriters' option to purchase additional shares. The Company expects that its cash and cash equivalents will be sufficient to fund its planned operations through 2024.

    Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

    ALX Oncology will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 AM Eastern Time. A live webcast of the presentation can be accessed here or by visiting the Investors section of ALX Oncology's website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the presentation dates.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology's website at www.alxoncology.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding ALX Oncology's clinical pipeline and the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of ALX148 in addition to key milestones such as anticipated clinical trial data readouts and cash and other financial expectations. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020, and other documents ALX Oncology subsequently files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

     



    Investor Contact:
    
    Peter Garcia
    Chief Financial Officer, ALX Oncology
    (650) 466-7125 Ext. 113
    
    
    Argot Partners
    (212)-600-1902
    
    
    Media Contact:
    
    Karen Sharma
    MacDougall
    (781) 235-3060
    

    Primary Logo

    View Full Article Hide Full Article
  2. BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.

    A live webcast of the presentation is available here and can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.

    About ALX Oncology

    BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.

    A live webcast of the presentation is available here and can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology's website at www.alxoncology.com.



    Investor Contact:
    
    Peter Garcia
    Chief Financial Officer, ALX Oncology
    (650) 466-7125 Ext. 113
    
    
    Argot Partners
    (212)-600-1902
    
    
    Media Contact:
    
    Karen Sharma
    MacDougall
    (781) 235-3060
    

    Primary Logo

    View Full Article Hide Full Article
  3. BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). ALX's addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

    The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted…

    BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). ALX's addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

    The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology's website at www.alxoncology.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020, and other documents ALX Oncology subsequently files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    Peter Garcia

    Chief Financial Officer, ALX Oncology

    (650) 466-7125 Ext. 113

    Argot Partners

    (212)-600-1902

    Media Contact:



    Karen Sharma

    MacDougall

    (781) 235-3060



    Primary Logo

    View Full Article Hide Full Article
  4. BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 357,000 additional shares of its common stock, at a price to the public of $76.00 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $208.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by ALX Oncology…

    BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 357,000 additional shares of its common stock, at a price to the public of $76.00 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $208.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by ALX Oncology. 

    Jefferies, Credit Suisse, and Piper Sandler acted as joint book-running managers for the offering. Cantor and UBS Investment Bank also acted as book-running managers for the offering. LifeSci Capital acted as lead manager for the offering.

    Registration statements relating to these securities became effective on December 9, 2020. The offering was made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at ; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at ; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at ; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, NY 10022, or by email at ; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML.

    Investor Contact:

    Peter Garcia

    Chief Financial Officer, ALX Oncology

    (650) 466-7125 Ext. 113

    Argot Partners

    (212)-600-1902

    Media Contact:

    Karen Sharma

    MacDougall

    (781) 235-3060



    Primary Logo

    View Full Article Hide Full Article
  5. BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the pricing of an upsized underwritten public offering of 2,380,000 shares of its common stock at a price of $76.00 per share. All of the shares of common stock are being offered by ALX Oncology. The gross proceeds to ALX Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ALX Oncology, are expected to be approximately $180.9 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close…

    BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the pricing of an upsized underwritten public offering of 2,380,000 shares of its common stock at a price of $76.00 per share. All of the shares of common stock are being offered by ALX Oncology. The gross proceeds to ALX Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ALX Oncology, are expected to be approximately $180.9 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on December 14, 2020, subject to the satisfaction of customary closing conditions. In addition, ALX Oncology has granted the underwriters a 30-day option to purchase up to an additional 357,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

    Jefferies, Credit Suisse, and Piper Sandler are acting as joint book-running managers for the offering. Cantor and UBS Investment Bank are also acting as book-running managers for the offering. LifeSci Capital is acting as lead manager for the offering.

    Registration statements relating to these securities became effective on December 9, 2020. The offering is made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at ; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at ; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at ; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, NY 10022, or by email at ; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275, or by email at . Copies of the final prospectus, when available, related to the offering will be available at www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Such forward-looking statements include, among other things, statements regarding the timing, size and completion of the public offering of common stock.  The forward-looking statements contained herein are based upon ALX Oncology's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the offering, and other risks. These and other risks are described more fully in ALX Oncology's registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC") on December 7, 2020 and the prospectus included therein, as well as ALX Oncology's other filings with the SEC from time to time, including its Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    Peter Garcia

    Chief Financial Officer, ALX Oncology

    (650) 466-7125 Ext. 113

    Argot Partners

    (212)-600-1902

    Media Contact:

    Karen Sharma

    MacDougall

    (781) 235-3060



    Primary Logo

    View Full Article Hide Full Article
View All ALX Oncology Holdings Inc. News